Vioxx And Bextra Get Split Votes From FDA Cmte. On Marketing
This article was originally published in The Pink Sheet Daily
Executive Summary
Vote slightly favors return of Vioxx to the market and continued marketing of Bextra. "Black box" warning on cardiovascular risk is recommended for COX-2s, including Pfizer's Celebrex. Restriction or banning of direct-to-consumer advertising also is advised by committee members.
You may also be interested in...
Arcoxia Advisory Committee Will Be Missing Key Participants From 2005 COX-2 Meeting
Many of the key panelists during the 2005 advisory committee review of COX-2 inhibitor cardiovascular safety will not be participating in the Arthritis Advisory Committee's April 12 review of Merck's Vioxx follow-on Arcoxia
Arcoxia Advisory Committee Will Be Missing Key Participants From 2005 COX-2 Meeting
Many of the key panelists during the 2005 advisory committee review of COX-2 inhibitor cardiovascular safety will not be participating in the Arthritis Advisory Committee's April 12 review of Merck's Vioxx follow-on Arcoxia
Bextra Pulled From Market, But Pfizer Hopes To Explore Other Options
Pfizer is characterizing FDA's request for a withdrawal of Bextra as a "marketing suspension"; the company hopes to continue discussions on how valdecoxib could re-enter the market. Increased cardiovascular risk plus a "special risk" of serious skin reactions led FDA to recommend pulling the COX-2 inhibitor.